Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company.
At the Teratology Society's annual meeting held in June at Las Croabas, Puerto Rico, Ecker reported preliminary results from a human test of an antisense
drug aimed at cytomegalovirus (CMV), a type of herpesvirus that can cause a vision-threatening eye infection for AIDS patients.
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE antisense
AVI's NEUGENE antisense
"rapid response therapeutics" may have a significant role to play in the future of bioterrorism defense.
The notice of allowance issued by the Canadian Intellectual Property Office is for a patent that covers basic use of antisense
RNA in all cells and cellular material (eukaryotic and prokaryotic alike), and broadly covers methods for regulating gene function in all cells using antisense
The study showed that treatment with antisense
inhibitors of ICAM-1 significantly prolonged heart transplant survival in mice in a dose-dependent manner and reduced damage to the transplanted heart.
molecule, this one directed against the RNA involved in the synthesis of a growth-regulating hormone, may prove useful against chronic myelogenous leukemia, says Alan M.
AVI believes its NEUGENE antisense
rapid response therapeutics will play a significant role in the future of antiviral therapeutics, including in treating emerging infectious diseases that threaten public health, or in addressing bioterrorism.
genetics is more than just a tool for customizing tomatoes.
Nasdaq:AVII), today presented preclinical data regarding the use of its NEUGENE([R]) antisense
technology against influenza A and E.
Nasdaq: ISIP), described data showing that antisense
drugs are therapeutically active in numerous animal models of disease and in human clinical studies.
Using a new genetic technology called antisense
, researchers have completely shut down the operation of a gene that can cause the walls of arteries to thicken, reducing blood flow to a trickle.
RNA was present in all five subjects available at twelve months post treatment.
Nasdaq: ISIP) announced today presentation of significant data demonstrating prolonged cardiac transplant survival in mice using an antisense
Recently, however, antisense
has blossomed into a high-stakes, big-bucks specialty, envisioned by its supproters as a revolutionizing force in clinical pharmacology.